nodes	percent_of_prediction	percent_of_DWPC	metapath
Travoprost—PTGFR—corpus luteum—breast cancer	0.136	0.647	CbGeAlD
Travoprost—PTGFR—nipple—breast cancer	0.0175	0.0829	CbGeAlD
Travoprost—PTGFR—uterus—breast cancer	0.00971	0.0461	CbGeAlD
Travoprost—PTGFR—adipose tissue—breast cancer	0.0095	0.0451	CbGeAlD
Travoprost—PTGFR—female reproductive system—breast cancer	0.00873	0.0415	CbGeAlD
Travoprost—PTGFR—adrenal gland—breast cancer	0.00852	0.0405	CbGeAlD
Travoprost—Carboprost Tromethamine—PTGER1—breast cancer	0.00826	0.424	CrCbGaD
Travoprost—PTGFR—female gonad—breast cancer	0.00794	0.0377	CbGeAlD
Travoprost—PTGFR—endocrine gland—breast cancer	0.00739	0.0351	CbGeAlD
Travoprost—Bimatoprost—PTGER1—breast cancer	0.00519	0.266	CrCbGaD
Travoprost—PTGFR—lymph node—breast cancer	0.00511	0.0243	CbGeAlD
Travoprost—Dinoprost Tromethamine—PTGER1—breast cancer	0.00314	0.161	CrCbGaD
Travoprost—Dinoprost Tromethamine—HPGDS—breast cancer	0.00214	0.11	CrCbGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—LPAR1—breast cancer	0.000877	0.00432	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—AGTR2—breast cancer	0.00081	0.00399	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CNR2—breast cancer	0.000807	0.00397	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—AGTR1—breast cancer	0.000806	0.00397	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—EDNRB—breast cancer	0.000776	0.00382	CbGpPWpGaD
Travoprost—Tafluprost—PTGS2—breast cancer	0.000746	0.0383	CrCbGaD
Travoprost—PTGFR—G alpha (q) signalling events—ITPR1—breast cancer	0.000723	0.00356	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—breast cancer	0.000721	0.00355	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—AGTR2—breast cancer	0.000694	0.00342	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL2—breast cancer	0.000694	0.00342	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CCL20—breast cancer	0.00069	0.0034	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—CXCR4—breast cancer	0.000689	0.00339	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—GPER1—breast cancer	0.000679	0.00334	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—LPAR1—breast cancer	0.000668	0.00329	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—EDNRB—breast cancer	0.000665	0.00327	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—STARD8—breast cancer	0.000664	0.00327	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—NMBR—breast cancer	0.000651	0.0032	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR1—breast cancer	0.000647	0.00318	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MMP3—breast cancer	0.000643	0.00316	CbGpPWpGaD
Travoprost—PTGFR—GPCRs, Class A Rhodopsin-like—AGTR1—breast cancer	0.000623	0.00307	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—GPER1—breast cancer	0.000616	0.00303	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CNR2—breast cancer	0.000615	0.00303	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PTGER1—breast cancer	0.000605	0.00298	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—NMBR—breast cancer	0.000591	0.00291	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCR4—breast cancer	0.00059	0.00291	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL12—breast cancer	0.00059	0.00291	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—WNT1—breast cancer	0.000578	0.00285	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PTGER1—breast cancer	0.000549	0.0027	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CCL27—breast cancer	0.000539	0.00265	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CXCL3—breast cancer	0.000539	0.00265	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PDE2A—breast cancer	0.000539	0.00265	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—AGTR1—breast cancer	0.000534	0.00263	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CXCL2—breast cancer	0.000529	0.0026	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—AGTR2—breast cancer	0.000529	0.0026	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—PTHLH—breast cancer	0.000523	0.00257	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—EDNRB—breast cancer	0.000506	0.00249	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—WNT10B—breast cancer	0.000502	0.00247	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CXCL3—breast cancer	0.00049	0.00241	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PDE2A—breast cancer	0.00049	0.00241	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CCL27—breast cancer	0.00049	0.00241	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CALCA—breast cancer	0.00046	0.00227	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CXCR4—breast cancer	0.00045	0.00221	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CXCL12—breast cancer	0.00045	0.00221	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—AGTR1—breast cancer	0.000407	0.002	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—RGS2—breast cancer	0.000394	0.00194	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CCL20—breast cancer	0.00039	0.00192	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCDC88C—breast cancer	0.000382	0.00188	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—LGR6—breast cancer	0.000382	0.00188	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—LPAR1—breast cancer	0.000378	0.00186	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—GPER1—breast cancer	0.000364	0.00179	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SFRP1—breast cancer	0.000364	0.00179	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—RGS2—breast cancer	0.000358	0.00176	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PDE4D—breast cancer	0.000357	0.00176	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CCL20—breast cancer	0.000354	0.00174	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—breast cancer	0.000352	0.00173	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NMBR—breast cancer	0.000349	0.00172	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CNR2—breast cancer	0.000347	0.00171	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—LPAR1—breast cancer	0.000343	0.00169	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CUL5—breast cancer	0.000324	0.0016	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PTGER1—breast cancer	0.000324	0.0016	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HEYL—breast cancer	0.000324	0.0016	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PDE4D—breast cancer	0.000324	0.00159	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CNR2—breast cancer	0.000315	0.00155	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—RSPO3—breast cancer	0.000305	0.0015	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—AGTR2—breast cancer	0.000299	0.00147	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CXCL2—breast cancer	0.000299	0.00147	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—WWOX—breast cancer	0.000297	0.00146	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—WNT10B—breast cancer	0.000297	0.00146	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—WNT1—breast cancer	0.000297	0.00146	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PTHLH—breast cancer	0.000295	0.00145	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PDE2A—breast cancer	0.000289	0.00142	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCL27—breast cancer	0.000289	0.00142	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—INHBB—breast cancer	0.000289	0.00142	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CXCL3—breast cancer	0.000289	0.00142	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—EDNRB—breast cancer	0.000286	0.00141	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—DLL4—breast cancer	0.000276	0.00136	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—BMPR2—breast cancer	0.000276	0.00136	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CXCL2—breast cancer	0.000271	0.00134	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—AGTR2—breast cancer	0.000271	0.00134	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PTHLH—breast cancer	0.000268	0.00132	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CDH5—breast cancer	0.000265	0.0013	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CALCA—breast cancer	0.00026	0.00128	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—EDNRB—breast cancer	0.00026	0.00128	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SFRP2—breast cancer	0.000259	0.00128	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PRLR—breast cancer	0.000255	0.00125	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CXCL12—breast cancer	0.000254	0.00125	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CXCR4—breast cancer	0.000254	0.00125	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—breast cancer	0.000254	0.00125	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—GLI2—breast cancer	0.000246	0.00121	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—VCP—breast cancer	0.000246	0.00121	CbGpPWpGaD
Travoprost—PTGFR—Class A/1 (Rhodopsin-like receptors)—CXCL8—breast cancer	0.000245	0.0012	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—LEPR—breast cancer	0.000242	0.00119	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—breast cancer	0.000241	0.00119	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CALCA—breast cancer	0.000236	0.00116	CbGpPWpGaD
Travoprost—PTGFR—G alpha (q) signalling events—PIK3CA—breast cancer	0.000234	0.00115	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CXCR4—breast cancer	0.000231	0.00114	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CXCL12—breast cancer	0.000231	0.00114	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—AGTR1—breast cancer	0.00023	0.00113	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—breast cancer	0.000228	0.00112	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—ARHGDIA—breast cancer	0.000225	0.00111	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FST—breast cancer	0.000219	0.00108	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HEY2—breast cancer	0.000217	0.00107	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—RPS6KB2—breast cancer	0.000214	0.00105	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—RGS2—breast cancer	0.000211	0.00104	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—breast cancer	0.00021	0.00103	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCL20—breast cancer	0.000209	0.00103	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—AGTR1—breast cancer	0.000209	0.00103	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—ITPR1—breast cancer	0.000206	0.00101	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TLE3—breast cancer	0.000203	0.000997	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—LPAR1—breast cancer	0.000203	0.000997	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HEY1—breast cancer	0.0002	0.000987	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—DLL1—breast cancer	0.000197	0.000968	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—breast cancer	0.000194	0.000954	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HIST1H2BC—breast cancer	0.000193	0.00095	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HIST1H2BK—breast cancer	0.000193	0.00095	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—GRB7—breast cancer	0.000191	0.000942	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PDE4D—breast cancer	0.000191	0.000942	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CSF2—breast cancer	0.00019	0.000937	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TAB2—breast cancer	0.000188	0.000925	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—ITPR1—breast cancer	0.000187	0.000922	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CNR2—breast cancer	0.000186	0.000918	CbGpPWpGaD
Travoprost—PTGFR—GPCR ligand binding—CXCL8—breast cancer	0.000186	0.000917	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—MMP3—breast cancer	0.000186	0.000915	CbGpPWpGaD
Travoprost—PTGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—breast cancer	0.000186	0.000913	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—DKK1—breast cancer	0.000182	0.000896	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—VEGFC—breast cancer	0.000181	0.000889	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—JAG2—breast cancer	0.000178	0.000875	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—WNT1—breast cancer	0.000175	0.000863	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—PLA2G4A—breast cancer	0.000175	0.000861	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CSF2—breast cancer	0.000173	0.000851	CbGpPWpGaD
Travoprost—Discomfort—Capecitabine—breast cancer	0.00017	0.000301	CcSEcCtD
Travoprost—Pruritus—Gemcitabine—breast cancer	0.00017	0.0003	CcSEcCtD
Travoprost—Nausea—Thiotepa—breast cancer	0.00017	0.0003	CcSEcCtD
Travoprost—Urethral disorder—Methotrexate—breast cancer	0.00017	0.0003	CcSEcCtD
Travoprost—Infection—Docetaxel—breast cancer	0.00017	0.000299	CcSEcCtD
Travoprost—Sinusitis—Epirubicin—breast cancer	0.000169	0.000299	CcSEcCtD
Travoprost—Diarrhoea—Mitoxantrone—breast cancer	0.000169	0.000298	CcSEcCtD
Travoprost—Diarrhoea—Irinotecan—breast cancer	0.000169	0.000298	CcSEcCtD
Travoprost—Dry mouth—Capecitabine—breast cancer	0.000169	0.000298	CcSEcCtD
Travoprost—Nervous system disorder—Docetaxel—breast cancer	0.000167	0.000295	CcSEcCtD
Travoprost—Pruritus—Fluorouracil—breast cancer	0.000167	0.000295	CcSEcCtD
Travoprost—Infestation—Doxorubicin—breast cancer	0.000167	0.000295	CcSEcCtD
Travoprost—Infestation NOS—Doxorubicin—breast cancer	0.000167	0.000295	CcSEcCtD
Travoprost—Visual impairment—Methotrexate—breast cancer	0.000167	0.000294	CcSEcCtD
Travoprost—Tachycardia—Docetaxel—breast cancer	0.000167	0.000294	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—NOTCH4—breast cancer	0.000166	0.000818	CbGpPWpGaD
Travoprost—Feeling abnormal—Paclitaxel—breast cancer	0.000166	0.000293	CcSEcCtD
Travoprost—Skin disorder—Docetaxel—breast cancer	0.000166	0.000293	CcSEcCtD
Travoprost—Oedema—Capecitabine—breast cancer	0.000165	0.000292	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—GZMB—breast cancer	0.000165	0.000813	CbGpPWpGaD
Travoprost—Bradycardia—Epirubicin—breast cancer	0.000165	0.000291	CcSEcCtD
Travoprost—Gastrointestinal pain—Paclitaxel—breast cancer	0.000165	0.000291	CcSEcCtD
Travoprost—Diarrhoea—Gemcitabine—breast cancer	0.000165	0.00029	CcSEcCtD
Travoprost—Infection—Capecitabine—breast cancer	0.000164	0.00029	CcSEcCtD
Travoprost—Dizziness—Irinotecan—breast cancer	0.000163	0.000288	CcSEcCtD
Travoprost—Rhinitis—Epirubicin—breast cancer	0.000163	0.000287	CcSEcCtD
Travoprost—Urinary tract infection—Doxorubicin—breast cancer	0.000162	0.000286	CcSEcCtD
Travoprost—Conjunctivitis—Doxorubicin—breast cancer	0.000162	0.000286	CcSEcCtD
Travoprost—Nervous system disorder—Capecitabine—breast cancer	0.000162	0.000286	CcSEcCtD
Travoprost—Eye disorder—Methotrexate—breast cancer	0.000162	0.000286	CcSEcCtD
Travoprost—Diarrhoea—Fluorouracil—breast cancer	0.000162	0.000286	CcSEcCtD
Travoprost—Tinnitus—Methotrexate—breast cancer	0.000161	0.000285	CcSEcCtD
Travoprost—Tachycardia—Capecitabine—breast cancer	0.000161	0.000285	CcSEcCtD
Travoprost—Pharyngitis—Epirubicin—breast cancer	0.000161	0.000284	CcSEcCtD
Travoprost—Cardiac disorder—Methotrexate—breast cancer	0.000161	0.000284	CcSEcCtD
Travoprost—Skin disorder—Capecitabine—breast cancer	0.000161	0.000283	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CXCL2—breast cancer	0.00016	0.000789	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—AGTR2—breast cancer	0.00016	0.000789	CbGpPWpGaD
Travoprost—Urinary tract disorder—Epirubicin—breast cancer	0.00016	0.000282	CcSEcCtD
Travoprost—Hypotension—Docetaxel—breast cancer	0.00016	0.000281	CcSEcCtD
Travoprost—Connective tissue disorder—Epirubicin—breast cancer	0.000159	0.000281	CcSEcCtD
Travoprost—Abdominal pain—Paclitaxel—breast cancer	0.000159	0.000281	CcSEcCtD
Travoprost—Urethral disorder—Epirubicin—breast cancer	0.000159	0.00028	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—BMP2—breast cancer	0.000158	0.00078	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PTHLH—breast cancer	0.000158	0.00078	CbGpPWpGaD
Travoprost—Angiopathy—Methotrexate—breast cancer	0.000157	0.000277	CcSEcCtD
Travoprost—Sinusitis—Doxorubicin—breast cancer	0.000157	0.000277	CcSEcCtD
Travoprost—Immune system disorder—Methotrexate—breast cancer	0.000156	0.000276	CcSEcCtD
Travoprost—Dizziness—Fluorouracil—breast cancer	0.000156	0.000276	CcSEcCtD
Travoprost—Visual impairment—Epirubicin—breast cancer	0.000156	0.000276	CcSEcCtD
Travoprost—Mediastinal disorder—Methotrexate—breast cancer	0.000156	0.000275	CcSEcCtD
Travoprost—Rash—Irinotecan—breast cancer	0.000156	0.000275	CcSEcCtD
Travoprost—Rash—Mitoxantrone—breast cancer	0.000156	0.000275	CcSEcCtD
Travoprost—Dermatitis—Mitoxantrone—breast cancer	0.000156	0.000274	CcSEcCtD
Travoprost—Dermatitis—Irinotecan—breast cancer	0.000156	0.000274	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Docetaxel—breast cancer	0.000156	0.000274	CcSEcCtD
Travoprost—Headache—Mitoxantrone—breast cancer	0.000155	0.000273	CcSEcCtD
Travoprost—Headache—Irinotecan—breast cancer	0.000155	0.000273	CcSEcCtD
Travoprost—Hypotension—Capecitabine—breast cancer	0.000154	0.000273	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—EDNRB—breast cancer	0.000153	0.000756	CbGpPWpGaD
Travoprost—Bradycardia—Doxorubicin—breast cancer	0.000153	0.000269	CcSEcCtD
Travoprost—Dyspnoea—Docetaxel—breast cancer	0.000152	0.000269	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PGR—breast cancer	0.000152	0.000748	CbGpPWpGaD
Travoprost—Mental disorder—Methotrexate—breast cancer	0.000152	0.000268	CcSEcCtD
Travoprost—Rash—Gemcitabine—breast cancer	0.000152	0.000268	CcSEcCtD
Travoprost—Dermatitis—Gemcitabine—breast cancer	0.000152	0.000267	CcSEcCtD
Travoprost—Eye disorder—Epirubicin—breast cancer	0.000151	0.000267	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—THBS1—breast cancer	0.000151	0.000744	CbGpPWpGaD
Travoprost—Tinnitus—Epirubicin—breast cancer	0.000151	0.000267	CcSEcCtD
Travoprost—Erythema—Methotrexate—breast cancer	0.000151	0.000266	CcSEcCtD
Travoprost—Headache—Gemcitabine—breast cancer	0.000151	0.000266	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Capecitabine—breast cancer	0.000151	0.000266	CcSEcCtD
Travoprost—Cardiac disorder—Epirubicin—breast cancer	0.00015	0.000265	CcSEcCtD
Travoprost—Rhinitis—Doxorubicin—breast cancer	0.00015	0.000265	CcSEcCtD
Travoprost—Dyspepsia—Docetaxel—breast cancer	0.00015	0.000265	CcSEcCtD
Travoprost—Rash—Fluorouracil—breast cancer	0.000149	0.000263	CcSEcCtD
Travoprost—Dermatitis—Fluorouracil—breast cancer	0.000149	0.000263	CcSEcCtD
Travoprost—Pharyngitis—Doxorubicin—breast cancer	0.000149	0.000263	CcSEcCtD
Travoprost—Hypersensitivity—Paclitaxel—breast cancer	0.000148	0.000262	CcSEcCtD
Travoprost—Headache—Fluorouracil—breast cancer	0.000148	0.000261	CcSEcCtD
Travoprost—Urinary tract disorder—Doxorubicin—breast cancer	0.000148	0.000261	CcSEcCtD
Travoprost—Dysgeusia—Methotrexate—breast cancer	0.000148	0.00026	CcSEcCtD
Travoprost—Gastrointestinal disorder—Docetaxel—breast cancer	0.000147	0.00026	CcSEcCtD
Travoprost—Connective tissue disorder—Doxorubicin—breast cancer	0.000147	0.00026	CcSEcCtD
Travoprost—Dyspnoea—Capecitabine—breast cancer	0.000147	0.00026	CcSEcCtD
Travoprost—Fatigue—Docetaxel—breast cancer	0.000147	0.00026	CcSEcCtD
Travoprost—Angiopathy—Epirubicin—breast cancer	0.000147	0.000259	CcSEcCtD
Travoprost—Urethral disorder—Doxorubicin—breast cancer	0.000147	0.000259	CcSEcCtD
Travoprost—Nausea—Mitoxantrone—breast cancer	0.000147	0.000259	CcSEcCtD
Travoprost—Nausea—Irinotecan—breast cancer	0.000147	0.000259	CcSEcCtD
Travoprost—Immune system disorder—Epirubicin—breast cancer	0.000146	0.000258	CcSEcCtD
Travoprost—Mediastinal disorder—Epirubicin—breast cancer	0.000146	0.000258	CcSEcCtD
Travoprost—Pain—Docetaxel—breast cancer	0.000146	0.000258	CcSEcCtD
Travoprost—Constipation—Docetaxel—breast cancer	0.000146	0.000258	CcSEcCtD
Travoprost—Back pain—Methotrexate—breast cancer	0.000146	0.000257	CcSEcCtD
Travoprost—Dyspepsia—Capecitabine—breast cancer	0.000146	0.000257	CcSEcCtD
Travoprost—Visual impairment—Doxorubicin—breast cancer	0.000145	0.000255	CcSEcCtD
Travoprost—Asthenia—Paclitaxel—breast cancer	0.000145	0.000255	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—FLT1—breast cancer	0.000144	0.00071	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FGF3—breast cancer	0.000144	0.000707	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SQSTM1—breast cancer	0.000144	0.000707	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CG—breast cancer	0.000143	0.000704	CbGpPWpGaD
Travoprost—Nausea—Gemcitabine—breast cancer	0.000143	0.000252	CcSEcCtD
Travoprost—Gastrointestinal disorder—Capecitabine—breast cancer	0.000143	0.000252	CcSEcCtD
Travoprost—Fatigue—Capecitabine—breast cancer	0.000143	0.000251	CcSEcCtD
Travoprost—Pruritus—Paclitaxel—breast cancer	0.000143	0.000251	CcSEcCtD
Travoprost—Vision blurred—Methotrexate—breast cancer	0.000142	0.000251	CcSEcCtD
Travoprost—Mental disorder—Epirubicin—breast cancer	0.000142	0.000251	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—JAG1—breast cancer	0.000142	0.000698	CbGpPWpGaD
Travoprost—Pain—Capecitabine—breast cancer	0.000141	0.000249	CcSEcCtD
Travoprost—Constipation—Capecitabine—breast cancer	0.000141	0.000249	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PARP1—breast cancer	0.000141	0.000695	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NOTCH3—breast cancer	0.000141	0.000695	CbGpPWpGaD
Travoprost—Erythema—Epirubicin—breast cancer	0.000141	0.000249	CcSEcCtD
Travoprost—Feeling abnormal—Docetaxel—breast cancer	0.000141	0.000248	CcSEcCtD
Travoprost—Nausea—Fluorouracil—breast cancer	0.000141	0.000248	CcSEcCtD
Travoprost—Eye disorder—Doxorubicin—breast cancer	0.00014	0.000247	CcSEcCtD
Travoprost—Ill-defined disorder—Methotrexate—breast cancer	0.00014	0.000247	CcSEcCtD
Travoprost—Tinnitus—Doxorubicin—breast cancer	0.00014	0.000247	CcSEcCtD
Travoprost—Gastrointestinal pain—Docetaxel—breast cancer	0.00014	0.000246	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CALCA—breast cancer	0.00014	0.000687	CbGpPWpGaD
Travoprost—Cardiac disorder—Doxorubicin—breast cancer	0.000139	0.000246	CcSEcCtD
Travoprost—Dysgeusia—Epirubicin—breast cancer	0.000138	0.000244	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—RPS6—breast cancer	0.000138	0.000679	CbGpPWpGaD
Travoprost—Diarrhoea—Paclitaxel—breast cancer	0.000138	0.000243	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—FGF4—breast cancer	0.000137	0.000673	CbGpPWpGaD
Travoprost—Back pain—Epirubicin—breast cancer	0.000136	0.000241	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CXCR4—breast cancer	0.000136	0.000671	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CXCL12—breast cancer	0.000136	0.000671	CbGpPWpGaD
Travoprost—Feeling abnormal—Capecitabine—breast cancer	0.000136	0.00024	CcSEcCtD
Travoprost—Angiopathy—Doxorubicin—breast cancer	0.000136	0.00024	CcSEcCtD
Travoprost—Malaise—Methotrexate—breast cancer	0.000136	0.00024	CcSEcCtD
Travoprost—Immune system disorder—Doxorubicin—breast cancer	0.000135	0.000239	CcSEcCtD
Travoprost—Vertigo—Methotrexate—breast cancer	0.000135	0.000239	CcSEcCtD
Travoprost—Gastrointestinal pain—Capecitabine—breast cancer	0.000135	0.000238	CcSEcCtD
Travoprost—Mediastinal disorder—Doxorubicin—breast cancer	0.000135	0.000238	CcSEcCtD
Travoprost—Abdominal pain—Docetaxel—breast cancer	0.000135	0.000238	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PAK1—breast cancer	0.000134	0.000659	CbGpPWpGaD
Travoprost—Dizziness—Paclitaxel—breast cancer	0.000133	0.000235	CcSEcCtD
Travoprost—Vision blurred—Epirubicin—breast cancer	0.000133	0.000235	CcSEcCtD
Travoprost—Cough—Methotrexate—breast cancer	0.000132	0.000232	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—TCF7L2—breast cancer	0.000131	0.000647	CbGpPWpGaD
Travoprost—Mental disorder—Doxorubicin—breast cancer	0.000131	0.000232	CcSEcCtD
Travoprost—Ill-defined disorder—Epirubicin—breast cancer	0.000131	0.000231	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—AKT2—breast cancer	0.000131	0.000644	CbGpPWpGaD
Travoprost—Abdominal pain—Capecitabine—breast cancer	0.000131	0.000231	CcSEcCtD
Travoprost—Erythema—Doxorubicin—breast cancer	0.000131	0.00023	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—PIK3CG—breast cancer	0.00013	0.000639	CbGpPWpGaD
Travoprost—Myalgia—Methotrexate—breast cancer	0.000128	0.000226	CcSEcCtD
Travoprost—Arthralgia—Methotrexate—breast cancer	0.000128	0.000226	CcSEcCtD
Travoprost—Chest pain—Methotrexate—breast cancer	0.000128	0.000226	CcSEcCtD
Travoprost—Dysgeusia—Doxorubicin—breast cancer	0.000128	0.000226	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	0.000127	0.000225	CcSEcCtD
Travoprost—Malaise—Epirubicin—breast cancer	0.000127	0.000224	CcSEcCtD
Travoprost—Rash—Paclitaxel—breast cancer	0.000127	0.000224	CcSEcCtD
Travoprost—Dermatitis—Paclitaxel—breast cancer	0.000127	0.000224	CcSEcCtD
Travoprost—Discomfort—Methotrexate—breast cancer	0.000127	0.000224	CcSEcCtD
Travoprost—Vertigo—Epirubicin—breast cancer	0.000127	0.000224	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—NOTCH2—breast cancer	0.000127	0.000624	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HSP90AA1—breast cancer	0.000127	0.000624	CbGpPWpGaD
Travoprost—Back pain—Doxorubicin—breast cancer	0.000126	0.000223	CcSEcCtD
Travoprost—Headache—Paclitaxel—breast cancer	0.000126	0.000223	CcSEcCtD
Travoprost—Hypersensitivity—Docetaxel—breast cancer	0.000126	0.000222	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CD—breast cancer	0.000126	0.000619	CbGpPWpGaD
Travoprost—Palpitations—Epirubicin—breast cancer	0.000125	0.00022	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—AGTR1—breast cancer	0.000123	0.000607	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PRL—breast cancer	0.000123	0.000607	CbGpPWpGaD
Travoprost—Cough—Epirubicin—breast cancer	0.000123	0.000217	CcSEcCtD
Travoprost—Vision blurred—Doxorubicin—breast cancer	0.000123	0.000217	CcSEcCtD
Travoprost—Asthenia—Docetaxel—breast cancer	0.000122	0.000216	CcSEcCtD
Travoprost—Infection—Methotrexate—breast cancer	0.000122	0.000216	CcSEcCtD
Travoprost—Hypertension—Epirubicin—breast cancer	0.000122	0.000215	CcSEcCtD
Travoprost—Hypersensitivity—Capecitabine—breast cancer	0.000122	0.000215	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—STK11—breast cancer	0.000121	0.000598	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—ADAM10—breast cancer	0.000121	0.000598	CbGpPWpGaD
Travoprost—Ill-defined disorder—Doxorubicin—breast cancer	0.000121	0.000214	CcSEcCtD
Travoprost—Pruritus—Docetaxel—breast cancer	0.000121	0.000213	CcSEcCtD
Travoprost—Nervous system disorder—Methotrexate—breast cancer	0.000121	0.000213	CcSEcCtD
Travoprost—Arthralgia—Epirubicin—breast cancer	0.00012	0.000212	CcSEcCtD
Travoprost—Chest pain—Epirubicin—breast cancer	0.00012	0.000212	CcSEcCtD
Travoprost—Myalgia—Epirubicin—breast cancer	0.00012	0.000212	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PLG—breast cancer	0.00012	0.000591	CbGpPWpGaD
Travoprost—Anxiety—Epirubicin—breast cancer	0.00012	0.000211	CcSEcCtD
Travoprost—Nausea—Paclitaxel—breast cancer	0.00012	0.000211	CcSEcCtD
Travoprost—Skin disorder—Methotrexate—breast cancer	0.00012	0.000211	CcSEcCtD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	0.000119	0.00021	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—AKT2—breast cancer	0.000119	0.000585	CbGpPWpGaD
Travoprost—Discomfort—Epirubicin—breast cancer	0.000119	0.000209	CcSEcCtD
Travoprost—Asthenia—Capecitabine—breast cancer	0.000119	0.000209	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—FGF10—breast cancer	0.000118	0.000582	CbGpPWpGaD
Travoprost—Malaise—Doxorubicin—breast cancer	0.000118	0.000208	CcSEcCtD
Travoprost—Dry mouth—Epirubicin—breast cancer	0.000117	0.000207	CcSEcCtD
Travoprost—Vertigo—Doxorubicin—breast cancer	0.000117	0.000207	CcSEcCtD
Travoprost—Pruritus—Capecitabine—breast cancer	0.000117	0.000206	CcSEcCtD
Travoprost—Diarrhoea—Docetaxel—breast cancer	0.000117	0.000206	CcSEcCtD
Travoprost—Palpitations—Doxorubicin—breast cancer	0.000115	0.000204	CcSEcCtD
Travoprost—Oedema—Epirubicin—breast cancer	0.000115	0.000203	CcSEcCtD
Travoprost—Hypotension—Methotrexate—breast cancer	0.000115	0.000203	CcSEcCtD
Travoprost—Infection—Epirubicin—breast cancer	0.000114	0.000202	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—PIK3CD—breast cancer	0.000114	0.000562	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PDGFA—breast cancer	0.000114	0.000561	CbGpPWpGaD
Travoprost—Cough—Doxorubicin—breast cancer	0.000114	0.000201	CcSEcCtD
Travoprost—Diarrhoea—Capecitabine—breast cancer	0.000113	0.0002	CcSEcCtD
Travoprost—Nervous system disorder—Epirubicin—breast cancer	0.000113	0.000199	CcSEcCtD
Travoprost—Dizziness—Docetaxel—breast cancer	0.000113	0.000199	CcSEcCtD
Travoprost—Hypertension—Doxorubicin—breast cancer	0.000113	0.000199	CcSEcCtD
Travoprost—Tachycardia—Epirubicin—breast cancer	0.000112	0.000198	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—TGFBR2—breast cancer	0.000112	0.000553	CbGpPWpGaD
Travoprost—Musculoskeletal discomfort—Methotrexate—breast cancer	0.000112	0.000198	CcSEcCtD
Travoprost—Skin disorder—Epirubicin—breast cancer	0.000112	0.000197	CcSEcCtD
Travoprost—Chest pain—Doxorubicin—breast cancer	0.000111	0.000196	CcSEcCtD
Travoprost—Myalgia—Doxorubicin—breast cancer	0.000111	0.000196	CcSEcCtD
Travoprost—Arthralgia—Doxorubicin—breast cancer	0.000111	0.000196	CcSEcCtD
Travoprost—Anxiety—Doxorubicin—breast cancer	0.000111	0.000195	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—ITPR1—breast cancer	0.000111	0.000544	CbGpPWpGaD
Travoprost—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	0.00011	0.000195	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—ERBB4—breast cancer	0.00011	0.000541	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—STAT5A—breast cancer	0.00011	0.000541	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MMP3—breast cancer	0.00011	0.000541	CbGpPWpGaD
Travoprost—Discomfort—Doxorubicin—breast cancer	0.00011	0.000194	CcSEcCtD
Travoprost—Dyspnoea—Methotrexate—breast cancer	0.00011	0.000194	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CB—breast cancer	0.00011	0.000539	CbGpPWpGaD
Travoprost—Dizziness—Capecitabine—breast cancer	0.000109	0.000193	CcSEcCtD
Travoprost—Dry mouth—Doxorubicin—breast cancer	0.000109	0.000192	CcSEcCtD
Travoprost—Dyspepsia—Methotrexate—breast cancer	0.000108	0.000191	CcSEcCtD
Travoprost—Rash—Docetaxel—breast cancer	0.000108	0.00019	CcSEcCtD
Travoprost—Hypotension—Epirubicin—breast cancer	0.000108	0.00019	CcSEcCtD
Travoprost—Dermatitis—Docetaxel—breast cancer	0.000108	0.00019	CcSEcCtD
Travoprost—Headache—Docetaxel—breast cancer	0.000107	0.000189	CcSEcCtD
Travoprost—Oedema—Doxorubicin—breast cancer	0.000107	0.000188	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—SMAD4—breast cancer	0.000106	0.000524	CbGpPWpGaD
Travoprost—Gastrointestinal disorder—Methotrexate—breast cancer	0.000106	0.000187	CcSEcCtD
Travoprost—Fatigue—Methotrexate—breast cancer	0.000106	0.000187	CcSEcCtD
Travoprost—Infection—Doxorubicin—breast cancer	0.000106	0.000187	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—IGF1R—breast cancer	0.000106	0.000521	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—CXCL8—breast cancer	0.000105	0.000518	CbGpPWpGaD
Travoprost—Pain—Methotrexate—breast cancer	0.000105	0.000186	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Epirubicin—breast cancer	0.000105	0.000185	CcSEcCtD
Travoprost—Nervous system disorder—Doxorubicin—breast cancer	0.000104	0.000184	CcSEcCtD
Travoprost—Rash—Capecitabine—breast cancer	0.000104	0.000184	CcSEcCtD
Travoprost—Dermatitis—Capecitabine—breast cancer	0.000104	0.000184	CcSEcCtD
Travoprost—Tachycardia—Doxorubicin—breast cancer	0.000104	0.000183	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—HES1—breast cancer	0.000104	0.000511	CbGpPWpGaD
Travoprost—Headache—Capecitabine—breast cancer	0.000104	0.000183	CcSEcCtD
Travoprost—Skin disorder—Doxorubicin—breast cancer	0.000103	0.000183	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—NCOR1—breast cancer	0.000103	0.000508	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PLA2G4A—breast cancer	0.000103	0.000508	CbGpPWpGaD
Travoprost—Dyspnoea—Epirubicin—breast cancer	0.000103	0.000181	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CSF2—breast cancer	0.000102	0.000503	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FGF1—breast cancer	0.000102	0.000503	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—RAF1—breast cancer	0.000102	0.000502	CbGpPWpGaD
Travoprost—Nausea—Docetaxel—breast cancer	0.000101	0.000179	CcSEcCtD
Travoprost—Feeling abnormal—Methotrexate—breast cancer	0.000101	0.000179	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—NRG1—breast cancer	0.000101	0.000499	CbGpPWpGaD
Travoprost—Dyspepsia—Epirubicin—breast cancer	0.000101	0.000179	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—H2AFX—breast cancer	0.000101	0.000495	CbGpPWpGaD
Travoprost—Gastrointestinal pain—Methotrexate—breast cancer	0.000101	0.000178	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—IL2—breast cancer	0.000101	0.000495	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—E2F1—breast cancer	9.99e-05	0.000492	CbGpPWpGaD
Travoprost—Hypotension—Doxorubicin—breast cancer	9.96e-05	0.000176	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—PIK3CB—breast cancer	9.95e-05	0.00049	CbGpPWpGaD
Travoprost—Gastrointestinal disorder—Epirubicin—breast cancer	9.94e-05	0.000175	CcSEcCtD
Travoprost—Fatigue—Epirubicin—breast cancer	9.93e-05	0.000175	CcSEcCtD
Travoprost—Pain—Epirubicin—breast cancer	9.85e-05	0.000174	CcSEcCtD
Travoprost—Constipation—Epirubicin—breast cancer	9.85e-05	0.000174	CcSEcCtD
Travoprost—Nausea—Capecitabine—breast cancer	9.82e-05	0.000173	CcSEcCtD
Travoprost—Abdominal pain—Methotrexate—breast cancer	9.73e-05	0.000172	CcSEcCtD
Travoprost—Musculoskeletal discomfort—Doxorubicin—breast cancer	9.71e-05	0.000171	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—SPP1—breast cancer	9.6e-05	0.000473	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—CXCL8—breast cancer	9.56e-05	0.000471	CbGpPWpGaD
Travoprost—Dyspnoea—Doxorubicin—breast cancer	9.5e-05	0.000168	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—ERBB3—breast cancer	9.5e-05	0.000468	CbGpPWpGaD
Travoprost—Feeling abnormal—Epirubicin—breast cancer	9.49e-05	0.000167	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—FGFR2—breast cancer	9.48e-05	0.000467	CbGpPWpGaD
Travoprost—Gastrointestinal pain—Epirubicin—breast cancer	9.42e-05	0.000166	CcSEcCtD
Travoprost—Dyspepsia—Doxorubicin—breast cancer	9.38e-05	0.000165	CcSEcCtD
Travoprost—Gastrointestinal disorder—Doxorubicin—breast cancer	9.2e-05	0.000162	CcSEcCtD
Travoprost—Fatigue—Doxorubicin—breast cancer	9.19e-05	0.000162	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—IL2—breast cancer	9.14e-05	0.00045	CbGpPWpGaD
Travoprost—Pain—Doxorubicin—breast cancer	9.11e-05	0.000161	CcSEcCtD
Travoprost—Constipation—Doxorubicin—breast cancer	9.11e-05	0.000161	CcSEcCtD
Travoprost—Abdominal pain—Epirubicin—breast cancer	9.1e-05	0.000161	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—TERT—breast cancer	9.1e-05	0.000448	CbGpPWpGaD
Travoprost—Hypersensitivity—Methotrexate—breast cancer	9.07e-05	0.00016	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—FGFR1—breast cancer	8.84e-05	0.000435	CbGpPWpGaD
Travoprost—Asthenia—Methotrexate—breast cancer	8.83e-05	0.000156	CcSEcCtD
Travoprost—Feeling abnormal—Doxorubicin—breast cancer	8.78e-05	0.000155	CcSEcCtD
Travoprost—Gastrointestinal pain—Doxorubicin—breast cancer	8.71e-05	0.000154	CcSEcCtD
Travoprost—Pruritus—Methotrexate—breast cancer	8.71e-05	0.000154	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—HIF1A—breast cancer	8.7e-05	0.000429	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—LEP—breast cancer	8.5e-05	0.000418	CbGpPWpGaD
Travoprost—Hypersensitivity—Epirubicin—breast cancer	8.48e-05	0.00015	CcSEcCtD
Travoprost—Abdominal pain—Doxorubicin—breast cancer	8.42e-05	0.000149	CcSEcCtD
Travoprost—Diarrhoea—Methotrexate—breast cancer	8.42e-05	0.000149	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—CAV1—breast cancer	8.42e-05	0.000414	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—KDR—breast cancer	8.32e-05	0.00041	CbGpPWpGaD
Travoprost—Asthenia—Epirubicin—breast cancer	8.26e-05	0.000146	CcSEcCtD
Travoprost—Pruritus—Epirubicin—breast cancer	8.15e-05	0.000144	CcSEcCtD
Travoprost—Dizziness—Methotrexate—breast cancer	8.14e-05	0.000144	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—ESR1—breast cancer	8.11e-05	0.000399	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—FN1—breast cancer	8.01e-05	0.000394	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NFKBIA—breast cancer	7.92e-05	0.00039	CbGpPWpGaD
Travoprost—Diarrhoea—Epirubicin—breast cancer	7.88e-05	0.000139	CcSEcCtD
Travoprost—Hypersensitivity—Doxorubicin—breast cancer	7.85e-05	0.000138	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—NOTCH1—breast cancer	7.84e-05	0.000386	CbGpPWpGaD
Travoprost—Rash—Methotrexate—breast cancer	7.76e-05	0.000137	CcSEcCtD
Travoprost—Dermatitis—Methotrexate—breast cancer	7.75e-05	0.000137	CcSEcCtD
Travoprost—Headache—Methotrexate—breast cancer	7.71e-05	0.000136	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—KIT—breast cancer	7.67e-05	0.000378	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—APC—breast cancer	7.67e-05	0.000378	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CG—breast cancer	7.67e-05	0.000378	CbGpPWpGaD
Travoprost—Asthenia—Doxorubicin—breast cancer	7.64e-05	0.000135	CcSEcCtD
Travoprost—Dizziness—Epirubicin—breast cancer	7.62e-05	0.000134	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—EGF—breast cancer	7.58e-05	0.000373	CbGpPWpGaD
Travoprost—Pruritus—Doxorubicin—breast cancer	7.54e-05	0.000133	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—MAPK3—breast cancer	7.34e-05	0.000362	CbGpPWpGaD
Travoprost—Nausea—Methotrexate—breast cancer	7.31e-05	0.000129	CcSEcCtD
Travoprost—Diarrhoea—Doxorubicin—breast cancer	7.29e-05	0.000129	CcSEcCtD
Travoprost—Rash—Epirubicin—breast cancer	7.26e-05	0.000128	CcSEcCtD
Travoprost—Dermatitis—Epirubicin—breast cancer	7.25e-05	0.000128	CcSEcCtD
Travoprost—Headache—Epirubicin—breast cancer	7.21e-05	0.000127	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—BRAF—breast cancer	7.21e-05	0.000355	CbGpPWpGaD
Travoprost—Dizziness—Doxorubicin—breast cancer	7.05e-05	0.000124	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—IGF1—breast cancer	7.02e-05	0.000346	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—AKT2—breast cancer	7.02e-05	0.000345	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—EGFR—breast cancer	6.99e-05	0.000344	CbGpPWpGaD
Travoprost—Nausea—Epirubicin—breast cancer	6.84e-05	0.000121	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—PIK3CD—breast cancer	6.74e-05	0.000332	CbGpPWpGaD
Travoprost—Rash—Doxorubicin—breast cancer	6.72e-05	0.000119	CcSEcCtD
Travoprost—Dermatitis—Doxorubicin—breast cancer	6.71e-05	0.000118	CcSEcCtD
Travoprost—PTGFR—GPCR downstream signaling—PIK3CA—breast cancer	6.68e-05	0.000329	CbGpPWpGaD
Travoprost—Headache—Doxorubicin—breast cancer	6.68e-05	0.000118	CcSEcCtD
Travoprost—PTGFR—Signaling Pathways—SERPINE1—breast cancer	6.67e-05	0.000328	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—KRAS—breast cancer	6.6e-05	0.000325	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—NOS3—breast cancer	6.37e-05	0.000313	CbGpPWpGaD
Travoprost—Nausea—Doxorubicin—breast cancer	6.33e-05	0.000112	CcSEcCtD
Travoprost—PTGFR—Signaling by GPCR—PIK3CA—breast cancer	6.06e-05	0.000299	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MDM2—breast cancer	6.04e-05	0.000297	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—RAF1—breast cancer	6.02e-05	0.000296	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—RELA—breast cancer	5.99e-05	0.000295	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—ERBB2—breast cancer	5.95e-05	0.000293	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MTOR—breast cancer	5.88e-05	0.000289	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CB—breast cancer	5.88e-05	0.000289	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CXCL8—breast cancer	5.65e-05	0.000278	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—HRAS—breast cancer	5.61e-05	0.000276	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CDKN1B—breast cancer	5.51e-05	0.000271	CbGpPWpGaD
Travoprost—PTGFR—GPCR downstream signaling—AKT1—breast cancer	5.45e-05	0.000269	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CASP3—breast cancer	5.4e-05	0.000266	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IL2—breast cancer	5.4e-05	0.000266	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—IL6—breast cancer	5.37e-05	0.000264	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CCND1—breast cancer	5.26e-05	0.000259	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—JUN—breast cancer	5.25e-05	0.000258	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CTNNB1—breast cancer	5.21e-05	0.000256	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MMP9—breast cancer	5.11e-05	0.000251	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—CDKN1A—breast cancer	5.09e-05	0.000251	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PTEN—breast cancer	5.08e-05	0.00025	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MAPK8—breast cancer	4.97e-05	0.000245	CbGpPWpGaD
Travoprost—PTGFR—Signaling by GPCR—AKT1—breast cancer	4.95e-05	0.000244	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—SRC—breast cancer	4.71e-05	0.000232	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—VEGFA—breast cancer	4.59e-05	0.000226	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—STAT3—breast cancer	4.54e-05	0.000224	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MAPK3—breast cancer	4.34e-05	0.000214	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—MYC—breast cancer	4.22e-05	0.000208	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TGFB1—breast cancer	4.21e-05	0.000207	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—EGFR—breast cancer	4.13e-05	0.000203	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—KRAS—breast cancer	3.9e-05	0.000192	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—PIK3CA—breast cancer	3.58e-05	0.000176	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—TP53—breast cancer	3.47e-05	0.000171	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—HRAS—breast cancer	3.31e-05	0.000163	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—IL6—breast cancer	3.17e-05	0.000156	CbGpPWpGaD
Travoprost—PTGFR—Signaling Pathways—AKT1—breast cancer	2.93e-05	0.000144	CbGpPWpGaD
